相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours
Eric Song et al.
NATURE (2020)
The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Shunjun Jiang et al.
ONCOLOGIST (2020)
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Inaki Eguren-Santamaria et al.
CLINICAL CANCER RESEARCH (2020)
CINeMA: An approach for assessing confidence in the results of a network meta-analysis
Adriani Nikolakopoulou et al.
PLOS MEDICINE (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Immune Checkpoint Inhibitors and Survival Outcomes in Brain Metastasis: A Time Series-Based Meta-Analysis
Xingjiang Hu et al.
FRONTIERS IN ONCOLOGY (2020)
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Sun Min Lim et al.
IMMUNE NETWORK (2020)
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
Konrad Pawelczyk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer
Manmeet S. Ahluwalia et al.
ONCOLOGIST (2018)
Changing paradigms of non-small cell lung cancer treatment
Francesco Guerrera et al.
JOURNAL OF THORACIC DISEASE (2018)
Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)
Z. Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Efficacy of Endostar Combined with Whole Brain Radiotherapy in Patients with NSCLC Brain Metastases
L. Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The Changing Paradigm of Treatment for Non-Small Cell Lung Cancer Intracranial Metastases
Gregory A. Azzam et al.
CURRENT PULMONOLOGY REPORTS (2018)
Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
Pierre Chabot et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial
Thomas M. Churilla et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Radiation-enhancing effect of sodium glycididazole in patients suffering from non-small cell lung cancer with multiple brain metastases: A randomized, placebo-controlled study
Y. C. Zeng et al.
CANCER RADIOTHERAPIE (2016)
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Paula Mulvenna et al.
LANCET (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson
CANCER BIOLOGY & MEDICINE (2016)
Ranking treatments in frequentist network meta-analysis works without resampling methods
Gerta Ruecker et al.
BMC MEDICAL RESEARCH METHODOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial
Hidefumi Aoyama et al.
JAMA ONCOLOGY (2015)
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer
S. H. Lim et al.
ANNALS OF ONCOLOGY (2015)
Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer
Feng Wang et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer
X. Jiang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Puey Ling Chia et al.
CLINICAL EPIDEMIOLOGY (2014)
The management of brain metastases in non-small cell lung cancer
Scott Owen et al.
FRONTIERS IN ONCOLOGY (2014)
A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study
Marco Ronald Hassler et al.
WIENER KLINISCHE WOCHENSCHRIFT (2013)
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Gianfranco A. Pesce et al.
EUROPEAN JOURNAL OF CANCER (2012)
A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer
Bjorn H. Gronberg et al.
LUNG CANCER (2012)
Whole-Brain Radiation Therapy Plus Concomitant Temozolomide for the Treatment of Brain Metastases From Non-Small-Cell Lung Cancer: A Randomized, Open-Label Phase II Study
Daniel Chua et al.
CLINICAL LUNG CANCER (2010)
First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer A Systematic Review
John Goffin et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
MOTEXAFIN GADOLINIUM COMBINED WITH PROMPT WHOLE BRAIN RADIOTHERAPY PROLONGS TIME TO NEUROLOGIC PROGRESSION IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES: RESULTS OF A PHASE III TRIAL
Minesh P. Mehta et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung
M Guerrieri et al.
LUNG CANCER (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
V Georgoulias et al.
LANCET (2001)
分享论文
